Status:
UNKNOWN
Anticoagulation in Gastroesophageal Varices and JAK2 Mutation
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Gastroesophageal Varices
JAK2 Mutation
Eligibility:
All Genders
18-75 years
Brief Summary
Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortal...
Eligibility Criteria
Inclusion
- Male or female patients aged 18-75
- diagnosed as portal hypertension by contrast-enhanced computed tomography
- diagnosed as JAK2 positive
Exclusion
- not had portal contrast-enhanced computed tomography
- not had JAK2 mutation test
- other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04527666
Start Date
October 1 2020
End Date
September 30 2022
Last Update
August 27 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.